Logo

Restore Medical’s ContraBand System Gains the US FDA’s Breakthrough Device Designation for Heart Failure with Reduced Ejection Fraction

Share this
Restore Medical

Restore Medical’s ContraBand System Gains the US FDA’s Breakthrough Device Designation for Heart Failure with Reduced Ejection Fraction

Shots:

  • The US FDA has granted BDD to the company’s ContraBand System for treating heart failure with reduced ejection fraction (HFrEF) in patients, symptomatic to optimal medical therapy, without significant pulmonary hypertension or right heart failure
  • The designation was supported by an ongoing feasibility trial that showed a reduction in left ventricular volume with improvements in hemodynamic function & physical capacity
  • ContraBand device is a minimally invasive transcatheter Pulmonary Artery Banding (PAB) system intended to improve quality of life in patients with left ventricle failure

Ref: PR Newswire | Image: Restore Medical

Related News:- Boehringer Ingelheim’s Jardiance Receives NICE Recommendation for Symptomatic Chronic Heart Failure with Preserved or Mildly Reduced Ejection Fraction

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions